ACR25 Best Abstracts – Day 4
ACR25 Best Abstracts – Day 4 jjcush@gmail.com Fri, 10/31/2025 – 15:52
ACR25 Best Abstracts – Day 4 jjcush@gmail.com Fri, 10/31/2025 – 15:52
Upadacitinib is a Double Edged Vascular Sword in GCA Dr. David Liew discusses abstracts O751, O738, and O734 presented https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg
Halloween ACR Guidance (10.31.25) jjcush@gmail.com Fri, 10/31/2025 – 15:47
Halloween ACR Guidance (10.31.25) jjcush@gmail.com Fri, 10/31/2025 – 15:47 Education/ACR/EULAR Anti-Rheumatic Rx Drug Safety Is Featured Off Show Author Off
Hospitalization in Stills: Is it “Still” an infection? Dr. Janet Pope discusses abstract 0163, “Trends in hospitalizat https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Fri,
Rheumatoid arthritis and the ‘big bang’ at #ACR25! Is there ‘bang for the buck’ using big data to help predic
RheumNow Rheumatology Round-Up https://t.co/eKcEoDEESO https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Fri, 10/31/2025 – 13:00 RheumNow Dr. John Cush RheumNow Rheumatology Round-Up https://t.co/eKcEoDEESO Dr. John
SLE Conference Preview: progress in biologics at #ACR25 We now have four licensed targeted therapies (i.e., belimumab, https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Fri,
Why I love the late breaking abstracts david.fl.liew@… Fri, 10/31/2025 – 10:47
Sexual Function in axSpA tammytilley@gm… Fri, 10/31/2025 – 08:00 Spondyloarthritis Dr. Antoni Chan reports on abstracts 2346 (Back in Action:
Psoriatic Arthritis Imaging Dr. Arthur Kavanaugh talks about imaging in psoriatic arthritis at #ACR25 https://t.co/l6M https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Thu, 10/30/2025 –
Lupus in Focus: 2025 ACR Treatment Guidelines for SLE Dr. Sheila Reyes reports on the scientific session presentation https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john…
Where are we at with PD-1 agonism? david.fl.liew@… Thu, 10/30/2025 – 18:15
Day 1 Recap: #ACR25 Highlights Join RheumNow Faculty Drs. Aurelie Najm, Yuz Yusof, Janet Pope, and Jack Cush for Day
RheumNow’s coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john…
Bone Density in Ankylosing Spondylitis Drbellamehta@g… Thu, 10/30/2025 – 15:00
GLP-1 Receptor Agonists in PsA: Mortality and MACE https://t.co/GtTGHY7j5g @synovialjoints discussed TriNetX data bas https://pbs.twimg.com/profile_images/1974180952390721536/r5ej4z9M_normal.jpg john+RNV2@john… Thu, 10/30/2025 – 14:12
Why are vaccine Abs maintained after CAR-T -depletion of pathogenic #Abs are dampened/eliminated Clonal repetoire expan https://pbs.twimg.com/profile_images/1007774150000332801/SjLeJk3G_normal.jpg john+RNV2@john… Thu, 10/30/2025
NEPTUNUS: Ianalumab in Sjogren’s https://t.co/K9Xm51Kb5X Finally good news in Sjogrens disease. @RheumNow #ACR25 https://pbs.twimg.com/profile_images/1974180952390721536/r5ej4z9M_normal.jpg john+RNV2@john… Thu, 10/30/2025 – 14:12 NoufAhmedAlham2
From Fitbit to first diagnosis: AI is rewriting the RA playbook Two studies presented at this year’s #ACR25 meeting h
Day 4 Recap: ACR Convergence 2025 Highlights https://t.co/CMpbzc4O5x Great discussion by @EBRheum @AkhilSoodMD @Dr_B https://pbs.twimg.com/profile_images/1974180952390721536/r5ej4z9M_normal.jpg john+RNV2@john… Thu, 10/30/2025 – 14:12
New Insights into Pregnancy Outcomes and Maternal-Fetal Health in Rheumatic Diseases At #ACR25, the ACR presented new https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Thu,
Predicting Rheumatoid Arthritis tammytilley@gm… Thu, 10/30/2025 – 12:41 Rheumatoid Arthritis Dr. Jonathan Kay reports on abstract 2260 (Generative AI model
Day 1 Recap: #ACR25 Highlights Join RheumNow Faculty Drs. Aurelie Najm, Yuz Yusof, Janet Pope and Jack Cush as they
IL-2 Therapy in SLE? Maybe tammytilley@gm… Thu, 10/30/2025 – 10:30 Lupus Dr. Janet Pope reports on abstract LB01 (Low-dose Interleukin-2
CAR T Which cells to target What patients & what disease When is right time In vivo (new) ex vivo
Prospective RCT on safety & efficacy of TAC+GC vs. MMF+GC TAC+GC was comparable to MMF+GC as continuous induction m https://pbs.twimg.com/profile_images/1027501556868870145/2culK0bN_normal.jpg